NCT06585488 2026-03-18
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
BeOne Medicines
Phase 1 Recruiting
Clinical Trials
14 trialsNCT07462442 2026-03-10
Study of QLS5308 in Patients With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT07108114 2026-02-23
SLV-324 Treatment of Metastatic Solid Tumors
Solve Therapeutics
Phase 1 Recruiting
NCT03388632 2025-12-18
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT07272590 2025-12-09
Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07087197 2025-12-08
A Study of SKB107 in Advanced Solid Tumors With Bone Metastases
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1 Recruiting
NCT04319198 2025-09-30
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
Gilead Sciences
Phase 4 Completed
NCT00878423 2024-08-02
Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors
Astex Pharmaceuticals, Inc.
Phase 1 Completed
NCT03523390 2024-02-23
Phase I/Ib Multiple Ascending Dose Study in China
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT03573544 2024-02-22
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
OBI Pharma, Inc
Phase 1/2 Terminated
NCT04457778 2023-12-08
First in Human Study of M6223
EMD Serono
Phase 1 Completed
NCT02235688 2022-02-10
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
ImmunityBio, Inc.
Phase 1 Completed
NCT00148993 2011-04-08
Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors
Hadassah Medical Organization
Phase 1/2 Withdrawn
NCT00149019 2011-04-08
Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.
Hadassah Medical Organization
Phase 2 Withdrawn